Literature DB >> 26051801

Decrease in catalytic capacity of γ-secretase can facilitate pathogenesis in sporadic and Familial Alzheimer's disease.

Željko M Svedružić1, Katarina Popović2, Vesna Šendula-Jengić3.   

Abstract

BACKGROUND: Alzheimer's disease can be a result of an age-induced disparity between increase in cellular metabolism of Aβ peptides and decrease in maximal activity of a membrane-embedded protease γ-secretase.
RESULTS: We compared activity of WT γ-secretase with the activity of 6 FAD mutants in its presenilin-1 component and 5 FAD mutants in Aβ-part of its APP substrate (Familial Alzheimer's disease). All 11 FAD mutations show linear correlation between the decrease in maximal activity and the clinically observed age-of-onset and age-of-death. Biphasic-inhibitors showed that a higher ratio between physiological Aβ-production and the maximal activity of γ-secretase can be observed in cells that can facilitate pathogenic changes in Aβ-products. For example, Aβ production in cells with WT γ-secretase is at 11% of its maximal activity, with delta-exon-9 mutant at 26%, while with M139V mutant is at 28% of the maximal activity. In the same conditions, G384A mutant is fully saturated and at its maximal activity. Similarly, Aβ production in cells with γ-secretase complex carrying Aph1AL component is 12% of its maximal activity, while in cells with Aph1B complex is 26% of its maximal activity. Similar to the cell-based studies, clinical studies of biphasic dose-response in plasma samples of 54 healthy individuals showed variable ratios between physiological Aβ production and the maximal activity of γ-secretase.
CONCLUSIONS: The increase in the ratio between physiological Aβ production and maximal activity of γ-secretase can be an early sign of pathogenic processes in enzyme-based, cell-based, and clinical studies of sporadic and Familiar Alzheimer's disease.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Early diagnostics; Familiar Alzheimer's disease mutations; Pathogenesis

Mesh:

Substances:

Year:  2015        PMID: 26051801     DOI: 10.1016/j.mcn.2015.06.002

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  5 in total

1.  [Progress on loss-of-function hypothesis of presenilin-1 mutations in Alzheimer diseases].

Authors:  Min Yan; Xu Wang; Xihan Guo
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-08-25

2.  Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer's Disease.

Authors:  Saima Zafar; Neelam Younas; Susana Correia; Mohsin Shafiq; Waqas Tahir; Matthias Schmitz; Isidre Ferrer; Olivier Andréoletti; Inga Zerr
Journal:  Mol Neurobiol       Date:  2016-01-14       Impact factor: 5.590

Review 3.  Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease.

Authors:  Fuyuki Kametani; Masato Hasegawa
Journal:  Front Neurosci       Date:  2018-01-30       Impact factor: 4.677

4.  In silico design of the first DNA-independent mechanism-based inhibitor of mammalian DNA methyltransferase Dnmt1.

Authors:  Vedran Miletić; Ivica Odorčić; Patrik Nikolić; Željko M Svedružić
Journal:  PLoS One       Date:  2017-04-11       Impact factor: 3.240

Review 5.  Presenilins as Drug Targets for Alzheimer's Disease-Recent Insights from Cell Biology and Electrophysiology as Novel Opportunities in Drug Development.

Authors:  R Scott Duncan; Bob Song; Peter Koulen
Journal:  Int J Mol Sci       Date:  2018-05-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.